Etanercept SFP in RA Patients
- Registration Number
- NCT00413452
- Lead Sponsor
- Amgen
- Brief Summary
Purpose of this study is to evaluate the immunogenicity and overall safety of etanercept SFP therapy administered once weekly for 24 weeks to subjects with rheumatoid arthritis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 224
Inclusion Criteria
- Men and women 18 years of age or older who have RA, as defined by the ACR criteria for classification of RA
- Naïve to etanercept therapy
- Able to self-inject investigational product or have a designee who can do so
- Ethical - Before any study-specific procedure, the appropriate written informed consent must be obtained Exclusion Criteria
- Receipt of Corticosteroids> 10 mg/day of prednisone (or its equivalent) during 14 days befor 1st dose of investigational product
- Receipt of MTX witin 30 days of 1st dose of investigational product
- Receipt of an other investigational drug within 30 days of 1st dose
- Receipt of TNF inhibitor therapy within 90 days of 1st dose
- Receipt of cyclophosphamide within 6 mo of 1st dose
- Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) greather than the maximum recommended dose in the product info sheet
- Current use of insulin
- gnificant concurrent medical condition
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 50 mg Etanercept 50 mg once weekly
- Primary Outcome Measures
Name Time Method Etanercept seroreactivity response (ie, development of anti-etanercept antibodies) to etanercept (manufactured using the SFP) 24 weeks
- Secondary Outcome Measures
Name Time Method Etanercept seroreactivity response to etanercept (manufactured using the SFP) week 12 neutralizing antibodies to etanercept week 12 and 24 Adverse events, serious adverse events (SAEs), serious infections and safety laboratory assessments week 24